(CercleFinance.com) – Liberum reaffirms its ‘buy’ recommendation on Bayer with a price target raised from 74 to 82 euros, after recent results which showed solid performances in all divisions and encouraging prospects for 2022.
The broker points in particular to significant progress in the pipeline which has improved the medium-term prospects of the pharmaceutical division, thus mentioning data on Nubeqa in hormone-sensitive prostate cancer.
“We look forward to early phase II data for Bayer’s new anticoagulant asundexian in early April, which could imply a long-term uplift for Xarelto,” Liberum adds.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
